Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Immunome Inc.IMNM · Entity 4219 | Chief Technical Officer | July 23, 2026 | July 27, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Immunome Inc.
Report date July 23, 2026 · Filed July 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 81,550 |
Reported balance
After 2026-07-23 transaction · row 1
1 source rowRow 1 · 2026-07-23 · Grant · Acquired 38,250 · Balance 81,550 F1: Represents the number of shares of the Issuer's common stock ("Common Stock") underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 25% of the RSUs will vest and settle into Common Stock annually on each anniversary of the grant date, subject to the Reporting Person's continuous service through each such vesting date. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.01 · Expires 2036-07-22 | Direct | 76,500 |
Reported balance
After 2026-07-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-07-23 · Grant · Acquired 76,500 · Balance 76,500 F2: 25% of the shares subject to the options vest on July 23, 2027, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter, subject to the Reporting Person's continuous service through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares of the Issuer's common stock ("Common Stock") underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 25% of the RSUs will vest and settle into Common Stock annually on each anniversary of the grant date, subject to the Reporting Person's continuous service through each such vesting date.
F2: 25% of the shares subject to the options vest on July 23, 2027, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter, subject to the Reporting Person's continuous service through each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 23, 2026 Filed Jul 27, 2026 20:10 UTC | Immunome Inc. IMNM · Entity 4219 | GrantEmployee Stock Option (right to buy) · Derivative | 76,500 | $0.00 Strike: $22.01 | $0.00 |
DisclosureSEC source: 0002026600-26-000002 · form4-07272026_040711.xml · derivative · entry 2 Tsai Philip · CIK 0002026600 · Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,500 Underlying: Common Stock · 76,500 shares Expires 2036-07-22 F2 · derivative.exercise_date: 25% of the shares subject to the options vest on July 23, 2027, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| July 23, 2026 Filed Jul 27, 2026 20:10 UTC | Immunome Inc. IMNM · Entity 4219 | GrantCommon Stock | 38,250 | $0.00 | $0.00 |
DisclosureSEC source: 0002026600-26-000002 · form4-07272026_040711.xml · nonDerivative · entry 1 Tsai Philip · CIK 0002026600 · Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,550 F1 · shares: Represents the number of shares of the Issuer's common stock ("Common Stock") underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 25% of the RSUs will vest and settle into Common Stock annually on each anniversary of the grant date, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| December 19, 2025 Filed Dec 22, 2025 12:32 UTC | Immunome Inc. IMNM · Entity 4219 | PurchaseCommon Stock | 10,000 | $20.49 | $204,900.00 |
DisclosureSEC source: 0002026600-25-000004 · form4-12222025_121251.xml · nonDerivative · entry 1 Tsai Philip · CIK 0002026600 · Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,300 Read SEC document |
| July 29, 2025 Filed Jul 31, 2025 23:00 UTC | Immunome Inc. IMNM · Entity 4219 | GrantEmployee Stock Option (right to buy) · Derivative | 190,000 | $0.00 Strike: $10.60 | $0.00 |
DisclosureSEC source: 0001415889-25-020788 · form4-07312025_110740.xml · derivative · entry 1 Tsai Philip · CIK 0002026600 · Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 190,000 Underlying: Common Stock · 190,000 shares Expires 2035-07-28 F1 · derivative.exercise_date: 25% of the shares subject to the options vest on July 29, 2026, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter. Read SEC document |
| March 24, 2025 Filed Mar 25, 2025 21:15 UTC | Immunome Inc. IMNM · Entity 4219 | PurchaseCommon Stock | 12,300 | $8.42 | $103,566.00 |
DisclosureSEC source: 0001415889-25-008918 · form4-03252025_090350.xml · nonDerivative · entry 1 Tsai Philip · CIK 0002026600 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,300 Read SEC document |
| November 21, 2024 Filed Nov 25, 2024 13:33 UTC | Immunome Inc. IMNM · Entity 4219 | PurchaseCommon Stock | 21,000 | $9.43 | $198,030.00 |
DisclosureSEC source: 0001415889-24-027597 · form4-11252024_011120.xml · nonDerivative · entry 1 Tsai Philip · CIK 0002026600 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,000 F1 · price: The purchase price for the reported transactions was $9.43. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, the Reporting Person will provide the full information regarding the securities purchased. Read SEC document |
| June 17, 2024 Filed Jun 19, 2024 01:08 UTC | Immunome Inc. IMNM · Entity 4219 | GrantStock option (right to buy) · Derivative | 250,000 | $0.00 Strike: $13.15 | $0.00 |
DisclosureSEC source: 0001415889-24-017531 · form4-06192024_010626.xml · derivative · entry 1 Tsai Philip · CIK 0002026600 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2034-06-16 F1 · derivative.exercise_date: 25% of the shares subject to the options vest on June 17, 2025, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.